A study conducted by Athira Pharma on 554 people with mild or moderate Alzheimer’s disease showed that patients who received the experimental injection fosgonimeton did not show a significant decline compared to those who received a placebo injection. The trial, known as LIFT-AD, did not demonstrate a difference in performance between the two groups on standard scales used to measure Alzheimer’s disease progression. This disappointing result comes after the company was embroiled in a data manipulation scandal, further adding to the challenges of developing effective treatments for Alzheimer’s.
Source link
Athira Alzheimer’s drug fails in trial
